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INTRODUCTION 
 
Hypertension is defined as any one of the following 
 
Systolic blood pressure  > 140mmHg 
Diastolic blood pressure > 90mmHg 
Taking any anti hypertensive Medication1 
 
Hypertension is a major cause of morbidity and mortality.  The heart, 
arterial vessels, brain, kidney and retinal vasculature are major target organs 
adversely affected by high blood pressure. In adults there is a continuous 
incremental risk of target organ damage across levels of both systolic and 
diastolic blood pressure. The multiple risk factor intervention trial (MRFIT) 
which included >3.5 lakh male participants, demonstrated a continuous and 
graded influence of both systolic and diastolic blood pressure on CHD 
mortality extending down to systolic blood pressure of 120mmHg. Cardio 
vascular disease risk doubles for every 20-mmHg systolic and 10-mm Hg 
diastolic rise in blood pressure.3 
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WHO/ ISH guidelines have indicated the following manifestations of 
target organ damage as factors influencing prognosis2 
 
1. Left ventricular hypertrophy 
 
2. Radiological evidence of atherosclerotic plaque 
 
3. Proteinuria / slight elevation of plasma creatinine concentration 
 
4. Generalised / focal narrowing of the retinal arteries  
 
Left ventricular hypertrophy is an independent risk factor to 
cardiovascular morbidity and mortality in hypertensive individuals4. 
.Identification of various geometric patterns of LV hypertrophy further 
stratifies cardiovascular risk.5, 6 
 
Microalbuminuria is a specific integrated marker of cardiovascular 
risk and target organ damage in primary hypertension and one that is 
suitable for identifying patients at higher global risk7. 11 Microalbuminuria is 
considered as strong, early and independent marker of increased 
cardiovascular risk in hypertension8 and risk is proportional to urine 
albumin excretion starting below conventional MAU threshold. 
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In hypertensive Patients, Micro-Albuminuria has significant 
association with concentric and eccentric LV hypertrophy10. Urine albumin 
creatinine ratio positively correlate with LV mass, systolic BP, age, pulse 
pressure and endocardial and mid-wall shortening but not to diastolic filling 
parameters.10 
 
Micro-albuminuria confers a four fold increased risk of Ischemic 
heart disease among hypertensive or borderline hypertensive subjects 13 
 
Micro-albuminuria is associated with atherogenic cardiovascular risk 
factors, endothelial dysfunction, impaired aortic mechanics and increased 
LV mass.14,16,17,18 Proteinuria, in hypertensive renal disease17,18,19,20 may 
accelerate the decline of renal function and also amplify the risk of vascular 
disease. Losartan Intervention for end point reduction in hypertension Study 
(LIFE study) indicates that changes in urine albumin excretion under 
antihypertensive treatment parallel those of ECG determined LV mass. 
Determination of albuminuria can become a useful tool in evaluation of 
global cardio vascular risk 21. 
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AIM:  
 
1. To study different cardiac geometry in newly diagnosed 
hypertensives.  
 
2. To correlate proteinuria and LV mass in hypertensives. 
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REVIEW OF LITERATURE 
 
 
Affecting one billion people worldwide and 118 million in India, 
systemic hypertension remains the most common, readily identifiable and 
reversible risk factor for myocardial infarction, stroke, heart failure, atrial 
fibrillation, aortic dissection and peripheral arterial diseases. The global 
burden of hypertension is projected to affect 1.5 billion persons, one third of 
world’s population, by the year 2025. 
 
 
Hypertension currently is defined as a usual BP of 140/90mm Hg or 
higher, or BP levels from which the benefits of pharmacological treatment 
have been definitively established in randomized placebo-controlled trials 
Studies have shown continuous positive relationships between the risk of 
coronary artery disease and stroke deaths with systolic or diastolic BP down 
to values as low as 115/75 mm of Hg. CAD is the most common cause of 
death from hypertension. 
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BLOOD PRESSURE VARIABILITY AND ITS DETERMINANTS 
 
a. Racial  
In hypertension, target organ damage and salt insensitive 
hypertension more common in US blacks.  
b. Smoking    
Cigarette smoking transiently raise BP by 10 to 20mm Hg with every 
cigarette, thereby elevating the day time BP in habitual smokers 
Smoking is associated with impaired coronary vasodilatation and 
inflammatory prothrombotic state. Moreover, rise in blood pressure is 
associated with intimal tear; all together contributing for premature 
atherosclerosis and coronary spam. 
c. Exercise  
Habitual physical inactivity is associated with markedly increased 
risk of developing hypertension, in part because of weight gain. 
d. Diet   
Excess consumption of calories and salt is associated with 
hypertension. Diets low in fresh fruit and potassium is associated with 
increased risk.25 Inter induvidual variability in BP responses to dietary 
sodium loading and sodium restriction indicates a genetic underpinning. 
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e. Obesity 
Obesity initially raises BP by increasing renal tubular reabsorption, 
impairing pressure natriuresis and causing volume expansion26 followed 
by progressive renal dysfunction  
 
Obesity is associated with 
a) Increased heart rate and cardiac output 27,28 
b) Concentric and eccentric cardiac hypertrophy 29,33 
c) Impaired systolic and diastolic function 30 
d) Endothelial dysfunction and arterial stiffness 31,32 
 
f. Genetics  
Fourteen genes involved in Mendelian form of hypertension have 
been suggested; mostly involving renal handling of salt and water; ACE 
polymorphism being a prominent example. 
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JNC – 7 STAGING OF OFFICE BLOOD PRESSURE34 
 
Blood pressure stage Systolic BP (mm Hg) 
Diastolic BP (mm 
Hg) 
Normal <120 <80 
Pre Hypertension 120-139 80-89 
St.1 Hypertension 140-159 90-99 
St.2. Hypertension >160 >100 
 
 
CLASSIFICATION OF BLOOD PRESSURE ACCORDING TO ESH 
(2003) (24) 
 
Category  Systolic  Diastolic 
Optimal <120  <80. 
Normal  120-129 80-84. 
High Normal  130-139 85-89. 
Grade I Hypertension 140-159 90-99. 
Grade II Hypertension 160-179 100-109. 
Grade III Hypertension       >180      >110. 
Isolated Systolic Hypertension  >140        <90. 
 
ESH – European Society of Hypertension 
 
 In ESH classification, staging of BP into grade 2 and 3 (stage II of 
JNC) better convey the concept of a continuous increase in risk with an 
increase in blood pressure.  As prehypertensive patients are considered to 
have high normal BP according to ESH classification, medicalisation of 
millions of people avoided (23). 
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HAEMODYNAMIC SUBTYPES  
 
a) Diastolic hypertension in middle age seen in middle aged men with 
weight gain,35 due to elevated peripheral resistance with 
inappropriately normal cardiac output. 
 
b) Combined systolic diastolic hypertension. 
  
c) Isolated systolic hypertension in older adults - After 60 years of age 
ISH is the most common36 form, defined as systolic BP higher than 
140mmHg and diastolic BP lower than 90mmHg. ISH is due to 
stiffening of central aorta and rapid return of reflected pulse waves 
from periphery.37 
  
d) Isolated systolic hypertension in young adults - Due to increased 
cardiac output and a stiff aorta; presumably reflecting an overactive 
sympathetic nervous system.38 
 
Pulse pressure, is due to the force imparted to the arterial blood 
column by left ventricular contraction. Pulse pressure after sixth decade of 
life is a surrogate risk marker of central artery stiffness 62; which is an 
independent risk factor for cardiovascular disease63. 
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NATURAL HISTORY OF ESSENTIAL HYPERTENSION 
  
 Essential hypertension is a heterogenous disorder. The probability of 
developing a morbid cardiovascular event with a given arterial pressure may 
vary by as much as twenty fold depending on whether associated risk 
factors are present or not.  Most untreated adults with hypertension will 
develop further increase in their arterial pressure with time. Further more it 
has been documented that untreated hypertensives are associated with a 
shortening of life by 10-20 yrs usually related to an acceleration of an 
atherosclerotic process with rate of acceleration in part related to the 
severity of the hypertension. 
 
 Even individuals with relatively mild disease left untreated for 7-10 
years have a high risk of developing significant complication. Nearly 36% 
will exhibit atherosclerotic complication and more than 50% will have end 
organ damage related to hypertension itself eg. Cardiomegaly, retinopathy 
and renal insufficiency. Thus even in its mild form, hypertension is a 
progressively lethal disease if left untreated. 
 
 Natural history of the disease for long range is available from series 
Natural course must come from data collected prior to the availability of 
effective treatment. Two such long series have been reported one by Perera 
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(1995) and other by Bechgaard. (Perera followed 500 patients with causal 
diastolic pressures of 90 mm Hg (or) higher, 150 from before onset and 350 
from an uncomplicated phase until their death.) 
 
 
(Data from Perera G.A. Journal of Chronic disease 1955, 1:33-42). 
 
 
Complications 
 
% Affected 
 
Mean Survival after 
onset (yrs) 
Cardiac Hypertrophy (X-ray) 74 8 
ECG 59 6 
CCF 50 4 
Angina 16 5 
Cerebral Encephalopathy 2 1 
Stroke 12 4 
Renal Proteinuria 42 5 
Elevated BU 18 1 
Accelerated Phase 7 1 
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Morbid Events in 196 Mild Hypertensives given Placebo for 7 yrs 
USPHS study 1977 (United States Public Health Service Hospital 
Study) 
 
Total events Rate / 100  
HT events 53.1  
CVA 
LVH 
LVH by ECG 
Cardiomegaly 
Retinopathy 
Rental Insufficiency 
CCF 
 
3.1 
12.8 
18.9 
11.7 
4.6 
1.0 
1.0 
Atherosclerotic 
 28.6  
MI 
Death 
Other Coronary Disease 
Arterial Insufficiency 
Treatment Failure 
 
7.1 
2.0 
18.9 
0.5 
12.1 
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BLOOD PRESSURE    = CARDIAC OUTPUT   X  PERIPHERAL RESISTANCE 
HYPERTENSION    = INCREASED CO AND /  OR INCREASED PR. 
  
 
Preload Contractility Functional 
Constriction 
Structural 
hypertorphy 
Fluid volume Volume  
Redistribution 
Excess sodium 
intake  
Renal 
sodium 
retention 
Decreased 
filtration 
surface 
Sympathetic 
nervous 
overactivity  
Renin  
angiotensin 
excess  
Cellmembrance 
alteration   
Hyper  
insulinemia    
Endothelin  
Derived  
factors     
Renal 
sodium 
retention Stress  
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TARGET ORGAN DAMAGE 
 
Left Ventricular Hypertrophy:- 
 
 In Hypertension, Left Ventricle undergoes hypertrophy as a 
compensatory mechanism to reduce wall stress and maintain pump function 
in the face of the increased after load. LVH is an important, independent 
predictor of mortality and morbidity. 39, 40. 
  
At which point LV mass cease to be compensatory and becomes 
deleterious in hypertension is not known, but the concept of inappropriate 
LV mass or excess mass beyond that predicted based on gender, body height 
and haemodynamic burden has been introduced to better address this issue 
41 42 43 Hypertension induces change in both contractile and supportive 
compartments of the heart that are maladaptive and detrimental.44 
  
Different patterns of adaption reflect the variable impact of preload 
on the LV due to changes in blood volume and venous compliance. 
 
Concentric Remodelling; with normal LV mass and increased relative 
wall thickness is a consequence of volume overload from pressure 
natriuresis cancelling out the effect of pressure overload.47 (Eccentric 
hypertrophy results from concomitant pressure and volume overload). 
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Concentric Hypertrophy is induced by pure pressure overload due to 
replication of sarcomeres in parallel: 45 associated with thickening of septal 
and posterior walls.  
 
Patients with LV hypertrophy are more likely to exhibit kidney 
damage, and increased carotid intima media thickness. 48 The risk of target 
organ damage can be further stratified by LV geometric pattern; the risk 
being highest with concentric and intermediate with eccentric hypertrophy.49 
Concentric remodelling; as well, is an independent predictor of increased 
cardiovascular risk in hypertensive patients. 47 The higher levels of blood 
pressure and neurohormonal activation likely explain risk of target organ 
damage. 
 
Concentric LV hypertrophy is associated with the greatest renal 
dysfunction and is likely to potentiate the decline in glomerular filtration 
rate with aging. 50 
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The close association between concentric geometry and 
cardiovascular events likely explained by a number of factors,- 
 
 
Abnormal diastolic filling  
 
Lower myocardial contractility 
 
Higher risk of arrhythmia  
 
Associated myocardial fibrosis 
 
Coronary Insufficiency 
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HAEMODYNAMICS AND CARDIAC PERFORMANCE ASSOCIATED WITH LV GEOMETRY IN 
HYPERTENSION 
 
 
 
Normal LV Concentric 
Remodelling 
Concentric 
Hypertrophy 
Eccentric 
Hypertrophy 
Prevalence 
 
52% 13% 8% 27% 
LV Mass 
 
- -  
 
 
Relative wall 
Thickness 
 
-   - 
Blood Pressure 
 
    
Stroke Index 
 
-  -  
Cardiac Index 
 
-  -  
Total Perepheral 
Resistance 
 
   - 
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LVH AND RISK OF CARDIOVASCULAR EVENTS 
 
Reference No. LVH criterion End point N/100Pt /yr 
    
With 
LVH 
Without 
LVH 
Castlie et al 
1986 
140 
LVMI 
>125g/m/m2 
Death/MI/stroke 4.6 1-2 
Levy et al 1989 3220 LVMI >116g/m2 Death/CV events
2 
2.3 
0.8 
1.4 
Koren et al 
1991 
280 LVMI>125g/m2 Death/CV events
1.4 
6.3 
0.1 
2.2 
Partrey et al 
1990 
104 
Wall Thickness 
>1.4cm 
Death 15.3 4.8 
 
 
Different studies; as shown above, have shown marked increase in 
mortality and morbidity in patients with LVH.  
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RENAL DYSFUNCTION 
 
A pivotal part of the renal body fluid feedback control system for 
long term blood pressure regulation is renal pressure natriuresis mechanism, 
whereby increased renal perfusion pressure lead to significant increase in 
sodium and water excretion.  
 
Impaired renal pressure natriuresis in seen in all forms of 
hypertension including essential hypertension. The shift of pressure 
natriuresis can be caused by intrarenal disturbances that increases tubular re-
absorption or reduce renal blood flow and glomerular filtration or extra 
renal disturbances like increased sympathetic nervous system activity or 
excessive formation of anti – natriuretic hormones like aldosterone. With 
long- standing hypertension, structural damage in the kidney may further 
shift pressure natriuresis and exacerbate hypertension. 
 
Segmental Hyalinosis of Inter lobular arteries and efferent arterioles 
reflect earliest hypertension induced intrarenal lesion. In early phase, 
capillary wall thickening and basement membrane thickening occurs which 
leads to focal and segmental glomerulosclerosis in malignant hypertension; 
ischemic collapse of glomerular tuft occurs. Benign hypertension is chara 
cterised by media thickening while malignant nephrosclerosis 
predominantly affect the intimal space. 
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Microalbuminuria and proteinuria are common in hypertensive 
disease. It may accelerate the decline of renal function and also amplify the 
risk of vascular disease. Microalbuminuria is also an independent risk factor 
for cardiovascular disease; even in general population microalbuminuria 
predict a small fall in creatinine clearance during 7years of follow up in 
patients with essential hypertension 
 
Micro albuminuria has been defined as urine albumin excretion of 30 
-300mg /24 hr OR 20-200µg/minute OR Albumin- creatinine ratio - 30 -
300µg/ mg of creatinine OR Protein Creatinine ratio > 30mg/ g in the first 
voided morning sample. Control of hypertension is the single most effective 
intervention for those with proteinuria. 
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CORONARY MICRO CIRCULATION ABNORMLITIES 
 
             In hypertensive patients with LVH, structural and functional 
alterations in the small coronary vessels, increasing ventricular wall stress 
and alterations in the rheological properties of blood inhibit the ability of the 
coronary micro circulation to regulate over all coronary blood flow. (52) 
 
CORONARY VESSEL PATHOLOGY IN LVH 
 
Rarefaction of arterioles – Inadequate growth of coronary micro 
vascular bed limit myocardial perfusion in the  presence of pressure – over 
load myocardial hypertrophy. (9) 
 
Medial wall thickening – Pressure overload with coronary arterial 
hypertension cause vascular medial hypertrophy with decreased lumen 
diameter and increased ratio of media thickness to lumen diameter. 
 
Perivascular and Interstial fibrosis 
 
 There will be increased vascular and perivascular deposition of 
collagen in LVH. 
 
Increased vascular water content 
 
A 10% to 15% increase in vessel wall water content is seen which 
produce thickening of the vascular walls. 
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Endothelial dysfunction  
 
An impaired endothelial dependent relaxation occurs before the 
development of overt hypertension. 
 
 Along with the above changes, there is alteration of coronary auto 
regulation and flow reserve with LVH. 
 
As in Framingham heart study, the Prevalence of silent MI was 
significantly increased in hypertensive subjects and they were also more 
susceptible for mortality.  After initial myocardial infarction there is 
increased mortality when diastolic BP is lower below 80mm Hg.  This                
J-Shaped curve probable reflects a reduction in perfusion pressure through 
the coronary vessels either narrowed or having impaired vasodilator reserve 
in the hypertrophied myocardium.    
       
 
COMPETING RISK FOR DIFFERENT CARDIOVASCULAR 
DISEASE OUT COMES IN HYPERTENSION. 
 
  A Recent analysis of Framingham heart study participants who 
experienced new - onset hypertension had shed light on the risks for CVD 
associated with hypertension.  In women and older men with new onset 
hypertension, stroke and heart failure were the most common first events, 
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while in younger men, hard CHD events.  These results may have important 
implication for primary preventive strategies. 
 
 
LV MASS REGRESSION 
 
Regression of LV mass with effective BP reduction has been in 
demonstrated in about 400 studies.  
 
In TOMHS, total cardiovascular events were reduced along with. LV 
mass regression. (64) Mid-wall fractional shortening, a sensitive indicator of 
intrinsic myocardial systolic performance, appears to improve with LV mass 
regression as well as stroke volume also improves. 
 
  LIFE study showed marked LV mass regression and proteinuria 
reduction in patients treated with losartan as compared with atenolol. 
 
TOMHS study shown as benefit of exercise on LV mass regression 
along with pharmalogical therapy. 
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Reduction of left Ventricular Mass Indexed By Surface Area With Different 
                                               Antihypertensive Drugs(65) 
 
 
 
 
Angiotensin
Receptor 
Antagonists 
Calcium 
Antagonists 
Angiotensin
converting 
Enzyme 
Inhibitors 
Diuretics 
 
Beta 
Blockers
 
Mean(%) 13 11 10 8 6 
95% Cl 8 to 18% 9 to 13% 8 to 12% 5 to 10% 3 to 8% 
 
 
GUIDELINES OF BLOOD PRESSURE MEASUREMENT 
 
 
The mercury sphygmomanometer is still considered the gold standard 
for BP measurement in the clinic  
 
The patient should be seated comfortably, uncover the location of cuff 
placement, with the legs uncrossed, the back and arm supported such that 
the middle of the cuff on the upper arm is at the level of the right atrium.  
BP measurements are influenced by the position of the arm in relation to the 
position of the chest. There is progressive increase in pressure of about 5-
6mmHg as the arm is moved down from the horizontal to vertical position. 
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2005 AHA RECOMMENDATION 
 
ARM 
CIRCUMFERENCE 
CUFF 
BLADDER 
WIDTH 
BLADDER 
LENGTH 
22-26cm small adult 10cm 24cm 
27-34cm Adult 13cm 30cm 
35-44cm Large adult 16cm 36cm 
45-52cm Adult thigh 16cm 42cm 
 
 
The cuff should be inflated to 10mmHg above the systolic pressure 
by palpatory method and deflated at a rate of 2-3mm Hg/ sec. American 
Heart Association and British Hypertension Society recommend fifth phase 
of Korotkoff sounds to be recorded as diastolic pressure. 
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METHODOLOGY 
 
STUDY METHOD 
Cross - Sectional Study 
 
SUBJECTS AND METHODS 
 
Fifty newly registered patients at hypertension clinic in Government 
Royapettah Hospital between February 2008 - July 2008 formed the 
material of the study. 
 
INCLUSION CRITERIA 
 
1. Newly detected patient with systolic BP > 140 mm hg and/or diastolic 
BP > 90 mmhg in atleast 2 visits. 
 
2. Age more than 40 years. 
 
3. No  clinical or lab evidence of heart failure, renal failure, coronary 
artery disease, valvular heart disease, secondary hypertension, 
hyperlipidemia, overt proteinuria, urinary tract infection. 
 
 
In all these patients, history of substance abuse, comprehensive 
clinical examination and appropriate imaging and bio-chemical evaluation 
done. 
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BLOOD PRESSURE 
 
BP recordings were taken with well-calibrated mercury 
sphygmomanometer and proper cuff size was selected so that bladder 
encircled atleast 2/3rd of arm about one inch above the right cubital fossa.  
Two measurements were taken on two different occasions while sitting 
comfortably with back supported. PhaseV of Korotkoffs sound was taken as 
diastolic BP. 
 
ECHO CARDIO GRAPHIC EXAMINATION 
 
 
      Echocardiography examination was performed at Department of 
Cardiology GRH, Chennai by an observer, unbiased of patient status.  Two 
– dimensional guided M-mode echocardiography was done standard 
parasternal and apical view observed with patient supine in left lateral 
position. 
  
      The left ventricular in cavity dimension (LVIDD) Inter ventricular 
septal thickness (IVSD) and left ventricle posterior wall thickness. 
(LVPWD) in diastole were measured. All measurements were done on 
frozen image.  All patients had good quality images suitable for 
measurement and interpretation. 
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CALCULATION 
 
Relative wall thickness. 
 
 
- Septal wall thickness + Posterior wall thickness 
                                       LV end – diastolic diameter 
 
 
LV mass was derived using formula by devereux and associates 
LV mass (grams) = 
0.8 x 1.04 [(ivsd + lvidd + pwtd) 3 – (lvdd) 3] +0.6 
IVSd - inter ventricular septal thickness at end - diastole. 
LVIDd - Left ventricular mass internal dimension at end - diastole  
PWTd - Posterior wall thickness at end – diastole. 
 
 
Left Ventricular mass index was inferred by calculating LV mass for 
body surface area taken as. 1.73m2 
 
Reference value of LVMI   
43 – 88     - for women 
49 – 102   - for men. 
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PROTEINURIA MEASUREMENT 
 
The morning spot urine sample protein – creatinine ratio has been 
measured using turbidimetric method (sulpho salicylic acid method) after 
ruling out overt proteinuria and cellular deposits. This method has an 
analytical sensitivity of 10mg/l. 
 
Concentric LV hypertrophy was considered  
              If RWT > 0.43 and LVH 
Eccentric LV hypertrophy was considered  
             If RWT < 0.43 and LVH. 
Concentric remodelling was considered 
If RWT > O.43 and normal LVMI.  
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OBSERVATION AND ANALYSIS  
 
AGE DISTRIBUTION 
 
TABLE-I 
 
 
 
 
 
 
 
Majority of patients in the study group were in fifth decade of life (44%) 
 
 
AGE GROUP FREQUENCY PERCENTAGE 
40-50 17 34% 
51-60 22 44% 
>60 11 22% 
Total 50 100% 
50 53.7200 7.10573 1.00490AGE
N Mean Std. Deviation
Std. Error
Mean
40 
TABLE- II 
 
SEX FREQUENCY PERCENTAGE 
Male 30 60% 
Female 20 40% 
Total 50 100% 
 
The study group consisted of 30 males and 20 females. 
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TABLE – III 
 
BMI (Body Mass Index 
(kg/m2) 
FREQUENCY PERCENTAGE  
18.5 - 23 23 46% 
23 - 30 27 54% 
Total 50 100% 
 
18.5 – 23 = Normal, 23 – 30 over weight, > 30 Obesity 
  
 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
BMI 50 23.56 2.53 .35 
 
 
In the study group, 23(48%) patients had normal BMI while 27 (54%) 
were over weight.  None of the patients were under nourished or obese. 
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STAGING OF HYPERTENSION ACCORDING TO JNC – 7 
CLASSIFICATION 
 
TABLE- IV  
 
STAGE OF 
HYPERTENSION 
FREQUENCY PERCENTAGE 
I (140-159) / (90-99) 24 48% 
II > 160/ >100 26 52% 
Total 50 100% 
 
 
Patient distribution between stage I and stage II were almost equal.
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TABLE – V 
 
PULSE PRESSURE FREQUENCY PERCENTAGE 
<=40 7 14% 
41-50 20 40% 
51-60 15 30% 
>60 8 16% 
Total 50 100% 
 
 
 
 N Mean Std. Deviation Std. Error Mean 
Pulse 
Pressure 
50 54.80 9.52 1.34 
 
Among the distribution of patients with pulse pressure gradient, 20 
patients (40%) had pulse pressure in the range of 41-50, 15 patients (30%) 
had pulse pressure in the range of 51-60.  7 (14%) and 8 (16%) had pulse 
pressure below 40 and above 60 respectively.  
44 
DISTRIBUTION OF DIFFERENT CARDIAC GEOMETRY IN 
PATENTS WITH ESSENTIAL HYPERTENSION 
 
TABLE-VI 
 
CARDIAC 
GEOMETRY 
FREQUENCY PERCENTAGE 
Normal Geometry  24 48 
Concentric Hypertrophy  7 14 
Concentric Remodelling  11 22 
Eccentric Hypertrophy  8 16 
Total 50 100 
 
 
Among 50 Patients, 26 patients (52%) had abnormal geometry, of 
which 11 patients had concentric remodelling, 8 patients had eccentric 
hypertrophy and 7 patients had concentric hypertrophy. 24 patients (48%) 
had normal geometry, having normal relative wall thickness and LV mass.  
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DISTRIBUTION OF URINE PROTEIN CREATININE RATIO IN 
MICRO – PROTEINURIA RANGE IN PATIENTS WITHOUT 
OVERT PROTEINURIA 
 
TABLE-VII 
 
URINE PROTEIN – 
CREATININE RATIO 
FREQUENCY PERCENTAGE 
Positive 18 36% 
Negative  32 64% 
Total 50 100% 
 
Positive – Urine PCR > 30 mg/g of Creatinine 
Negative – Urine PCR < 30 mg/g of Creatinine 
  
In the study, 18 patients (36%) had urine protein in Mircoproteinuria 
range as detected by early morning spot urine protein - creatinine ratio.  
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DISTRIBUTION OF PCR FOR DIFFERENT AGE BMI AND PULSE 
PRESSURE 
 
PCR N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Positive 18 60.55 8.72 2.05 Pulse 
Pressure Negative 32 51.56 8.46 1.49 
 
PCR N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Positive 18 25.00 2.44 .57 
BMI 
Negative 32 22.75 2.22 .39 
 
 PCR   
Positive  Negative  
Total 
AGE 
GROUP 
40-50  2 
(11%) 
15 
(47%) 
17 
 51-60 12 
(66.7%) 
10 
(31.3%) 
22 
 > 60 4 
(22.2%) 
7 
(21.9%) 
11 
Total   18 32 50 
 
p-value - .02  
Positive PCR was distributed in mean pulse pressure of 60 and BMI of 25. 
Negative PCR was distributed in mean pulse pressure of 51 and BMI of 22. 
Majority of patents with MAU was in age group 51 - 60. 
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DISTRIBUTION OF LV GEOMETRY FOR DIFFERENT AGE BMI 
AND PULSE PRESSURE  
 
Geometry group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Normal 24 53.29 8.14 1.66 
Age 
Abnormal 26 54.11 6.13 1.2 
   
P=0.687 NOT SIGNIFICANT. 
 
 
Geometry group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Normal 24 22.83 2.38 .48 
BMI 
Abnormal 26 24.23 2.5 .49 
p value -0.05 
 
 
Geometry group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Normal 24 52.91 9.07 1.85 Pulse 
Pressure Abnormal 26 56.53 9.77 1.91 
p value- 0.18 
 
For LVH, mean age was 54, BMI was 24 and Pulse Pressure was 56.5.  
 
For Normal geometry mean age was 53, BMI was 22.8 and Pulse Pressure 
was 52.      
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ASSOCIATION BETWEEN URINE PROTEIN – CREATININE 
RATIO & ABNORMAL CARDIAC GEOMETRY 
 
TABLE- VIII - A 
 
PCR Normal Abnormal 
Positive 
3 
(16.7%) 
[12.5%] 
15 
(83.3%) 
[57.7%] 
Negative 
21 
(65.6%) 
[87.5%] 
11 
(34.4%) 
[42.3%] 
Total 24 26 
 
p-value = 0.001(Pearson) 
 
Among 18 patients with Micro- Proteinuria, 15 patients (83%) had 
abnormal cardiac geometry. Among 26 patients with abnormal cardiac 
geometry, 15 patients (58%) had microproteinuria. 
 
There is significant association between microproteinuria and 
abnormal cardiac geometry in patients with essential hypertension.  
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ASSOCIATION BETWEEN URINE PROTEIN CREATININE 
RATIO AND CARDIAC GEOMETRY IN HYPERTENSION 
 
 
TABLE – VIII - B  
 
Urine PCR  
Cardiac Geometry 
Positive Negative 
Total 
Normal Geometry 
3 
(12.5%) 
[16.7%] 
21 
(87.5%) 
[65.6%] 
24 
48.0 
 
Concentric Hypertrophy 
6 
(85.7%) 
[33.3%] 
1 
(14.3%) 
[3.1%] 
7 
14.0 
 
Concentric Remodelling 
6 
(54.5%) 
[33.3%] 
5 
(45.5%) 
[15.6%] 
11 
22.0 
Eccentric Hypertrophy 
 
3 
(37.5%) 
[16.7%] 
5 
(62.5%) 
[15.6%] 
8 
16.0 
Total 
18 
36.0 
32 
64.0 
50 
100.0 
 
p- value = 0.00189 (Pearson)    
  
 
Among 18 patients with microproteinuria both concentric 
hypertrophy and concentric remodelling have 33.3% prevalence. 
Both normal geometry and eccentric hypertrophy had 16.7% 
50 
prevalence. Among 32 patients without proteinuria, 21 (65.6%) 
had normal geometry  
 
Among 7 patients with concentric hypertrophy, 6 (85.7%) 
had microproteinuria.  
 
Among ii patients with concentric remodelling, 6 (54.5%) 
had microproteinuria.  
 
Among 8 patients with eccentric hypertrophy, 3 (37.5%) had 
microproteinuria.  
 
Among 24 patients with normal geometry, only 3 (12.5%) 
had microproteinuria.   
51 
ASSOCIATION BETWEEN URINE PCR AND SMOKING 
 
TABLE – IX - A 
 
 
 
p-value = 0.009 (Pearson) 
 
Among 14 smokers, 9 (64%) had microproteinuria showing a 
significant association between smoking and microproteinuria   
 
 
 
 
 
 
 
 
SMOKING  URINE PCR  
Yes No Total 
Positive 9 
(50%) 
[64.3%] 
9 
(50%) 
[25%] 
18 
36.0% 
Negative 5 
(15.6%) 
[35.7%] 
27 
(84.4%) 
[75.0%] 
32 
64.0% 
Total 14 
28.0% 
36 
72.0% 
50 
100.0% 
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ASSOCIATION BETWEEN LVH AND SMOKING 
 
TABLE – IX - B 
 
GEOMETRY GROUP    
Normal   Abnormal  
Total 
SMOKING No 
22 
(91.7%) 
17 
(65.4%) 
39 
 Yes 
2 
(8.3%) 
9 
(34.6%) 
11 
Total  24 26 50 
 
p value-0.02 
 
Among 11 smoker, 9 (82%) had LVH. While smoker represented 
35% of LVH patients. A significant association was seen between smoking 
LVH.       
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ASSOCIATION BETWEEN PULSE PRESSURE AND CARDIAC 
GEOMETRY 
 
TABLE - X 
 
CARDIAC GEOMETRY  PULSE 
PRESSURE  Normal Abnormal Total 
<= 40 
5 
(71.4%) 
[20.8%] 
2 
(28.6%) 
[7.7%] 
7 
14.0% 
41-50 
12 
(60.0%) 
[50.0%] 
8 
(40.0%) 
[30.8%] 
20 
40.0% 
51-60 
4 
(26.7%) 
[16.7%] 
11 
(73.3%) 
[42.3%] 
15 
30.0% 
>60 
3 
(37.5%) 
[12.5%] 
5 
(62.5%) 
[19.2%] 
8 
16.0% 
 
Total 24 48.0% 
26 
52.0% 
50 
100.0% 
 
p-value = 0.04746 (Mantel – Haenszel) 
 
Among 8 patients with pulse pressure >60, (62.5%) had abnormal 
cardiac geometry out of 15 patients with pulse pressure 51-60, 11 (73%) had 
LVH. In patients with pulse pressure less than 40 and 40-50, majority had 
normal cardiac geometry. There is a significant association between 
widened pulse pressure and abnormal cardiac geometry.   
 
 
54 
ASSOCIATION BETWEEN CARDIAC GEOMETRY AND STAGE 
OF HYPERTENSION 
 
TABLE –XI - A 
 
Cardiac Geometry 
STAGE 
Normal Abnormal 
Total 
I 
18 
(75.0%) 
[75.0%] 
6 
(25.0%) 
[23.1%] 
24 
48.0 
II 
6 
(23.1%) 
[25.0%] 
20 
(76.9%) 
[76.9%] 
26 
52.0 
Total 24 48.0 
26 
52.0 
50 
100.0 
  
p-value = 0.00024 (Pearson) 
 
STAGE - I – 140 – 159 
            80-89 mmHg 
STAGE – II - > 160/ > 90 mmHg 
 
 
 
 
Among 26 patients with stage II hypertension, 20 patients (77%) had 
LVH, while 18 patients (75%) with stage I had normal cardiac geometry. 
There was a strong positive association between stage II hypertension and 
LVH.  
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ASSOCIATION BETWEEN CARDIAC GEOMETRY AND STAGE 
OF HYPERTENSION 
 
TABLE –XI - B 
  
CARDIAC GEOMETRY Total STAGE 
NG CH CR EH   
I 
18 
(75.0%) 
[75.0%] 
1 
(4.2%) 
[14.3%] 
4 
(16.7%) 
[36.4%] 
1 
(4.2%) 
[12.5%] 
24 
48.0 
II 
6 
(23.1%) 
[25.0%] 
6 
(23.1%) 
[85.7%] 
7 
(26.9%) 
[63.6%] 
7 
(26.9%) 
[87.5%] 
26 
52.0 
Total 24 48.0 
7 
14 
11 
52.0 
8 
16 
50 
100.0 
 
p – value = 0.00197 (Pearson)   
 
Majority of patients (85.7%) with concentric hypertrophy had stage II 
hypertension; 87.5% patients with eccentric hypertrophy and 63.6% with 
concentric remodeling had stage II hypertension.    
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ASSOCIATION BETWEEN STAGE OF HYPERTENSION AND 
URINE PROTEIN CREATININE RATIO 
 
TABLE – XII  
 
 
STAGE POSITIVE NEGATIVE TOTAL 
I 
5 
(20.8%) 
[27.8%] 
19 
(79.2%) 
[59.4%] 
24 
48.0 
 
II 
13 
(50.0%) 
[72.2%] 
13 
(50.0%) 
[40.6%] 
26 
52.0 
 
Total 18 
36.0 
32 
64.0 
50 
100.0 
 
p- value = 0.03182 (Pearson)     
 
 
Among 18 patients with micro-proteinuria, 13 (72%) had stage II 
hypertension. While 13 (50%) of patients with stage II had proteinuria, only 
5 (20%) with stage I hypertension had proteinuria.     
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ASSOCIATION BETWEEN CARDIAC GEOMETRY AND BODY 
MASS INDEX  
 
TABLE - XIII    
 
 
CARDIAC GEOMETRY
BMI 
Normal Abnormal
Total 
<= 23 
16 
(69.6%) 
[66.7%] 
7 
(30.4%) 
[26.9%] 
23 
46.0 
> 23 
8 
(29.6%) 
[33.3%] 
19 
(70.4%) 
[73.1%] 
27 
54.0 
Total 
24 
48.0 
26 
52.0 
50 
100.0 
 
p- value = 0.00485 (Pearson)      
 
BMI - < 23 – Normal 
  23-30 – Overweight 
 
 
Out of 27 overweight patients 19 (70.4%) have LVH. 
 
Among 26 patients with LVH 19 (73.1%) were overweight  
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ASSOCIATION BETWEEN BMI AND URINE PROTEIN 
CREATINE RATIO 
 
TABLE – XIV 
  
Urine PCR 
BMI 
Positive Negative 
Total 
<= 23 
4 
(17.4%) 
[22.2%] 
19 
(82.6%) 
[59.4%] 
23 
46.0 
 
> 23 
14 
(51.9%) 
[77.8%] 
13 
(48.1%) 
[40.6%] 
27 
54.0 
 
Total 18 
36.0 
32 
64.0 
50 
100.0 
 
 
  While 14 patients (77.8%) with microproteinuria were having 
overweight, the distribution of over weight patients between those with and 
without proteinuria were equal.  
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ASSOCIATION BETWEEN URINE PCR AND CARDIAC 
GEOMETRY IN PATIENTS WITH STAGE II HYPERTENSION 
 
TABLE – XV - A  
 
Cardiac geometry Urine PCR Normal Abnormal Total 
Positive 
1 
(7.2%) 
[14.3%] 
13 
(92.8%) 
[68.4%] 
14 
Negative 
6 
(50.6%) 
[85.7%] 
6 
(50%) 
[31.6%] 
12 
 7 (27%) 
19 
(73%) 
 
 
 
 
Among 26 patients with stage II hypertension, 19 patients 
(73%) have LVH of which 13 (68.4%) had microproteinuria. 
 
Out of 14 patients (53.8%) in stage II hypertension having 
microproteinuria, 13 (92.8%) had LVH.   
 
Among 7 patients having normal geometry only 1 (14%) had 
microproteinuria.  
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ASSOCIATION BETWEEN URINE PCR AND CARDIAC 
GEOMETRY IN PATIENTS WITH STAGE I HYPERTENSION 
 
TABLE – XV - B  
 
 
Cardiac geometry Urine PCR Normal Abnormal Total 
Positive 
2 
(40%) 
[11.1%] 
3 
(60%) 
[50. %] 
5 
Negative 
16 
(84.3%) 
[88.9%] 
3 
(15.7%) 
[50%] 
19 
 18 75% 
6 
25%  
 
 
Among 24 patients in stage I hypertension, 18 (75%) had normal 
cardiac geometry only 6 (25%) had LVH and 5 (21%) had microproteinuria.  
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BINARY LOGISTIC REGRESSION MODEL FOR DIFFERENT 
FACTORS WITH LVH    
 
     
FACTORS CHI- SQUARE P- VALUE 
SEX 1.410 .235 
BMI .078 .78 
STAGE OF HTN 5.5 .018 
PP .34 .55 
SMOKING 3.77 .05 
AGE .29 .58 
 
When regression model was applied for studying association between 
different factors and LVH only staging of hypertension (Stage II) showed a 
positive association.   
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BINARY LOGISTIC REGRESSION MODEL FOR DIFFERENT 
FACTORS WITH MICROPROTEINURIA 
 
 
FACTORS CHI- SQUARE P- VALUE 
SEX 0.5 0.47 
BMI 2.1 .13 
STAGE OF HTN .002 .96 
PP 2.3 .12 
SMOKING 2.7 .07 
AGE 3.7 .05 
CARDIAC GEOMETRY 4.2 .039 
 
When regression model was applied for studying association between 
different factors and PCR only Abnormal cardiac geometry showed a 
positive association.  
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 DISCUSSION 
 
Study was conducted in 50 newly detected hypertensives in the age 
group of 40-70-years of age with 60% females and 40% male.  Most of the 
patients were in 40-50 years of age group. 
 
Among 30 males, 14 were smokers (46%) 
 
Out of 50 patients, 27 (54%) were having a body mass index 
consistent with overweight (23-30), 23(46%) were having normal BMI. 
 
As per JNC-7 staging of hypertension, 24 (48%) of patients were in 
stage I and 26 (52%) were in stage - II 
 
Out of 50 patients, 26 (52%) had unfavourable cardiac geometry.  
Among patients with unfavourable cardiac geometry, 11 patients (22%) had 
concentric remodelling, 8 (16%) had eccentric hypertrophy and 7 (14%) had 
concentric hypertrophy. 
 
The urine protein creatinine ratio was in microalbuminuria range in 
18 (36%) patients of which 15 (83%) had abnormal cardiac geometry,          
3 (17%) had normal cardiac geometry; showing a significant association 
between proteinuria and left ventricular hypertrophy in patients with 
essential hypertension. 
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  Among 14 (48%) patients with smoking habit out of 30 males in the 
study, 9 (64%) had proteinuria. A significant association was seen between 
proteinuria and smoking.  
 
A significant association was seen between widened pulse pressure 
and abnormal cardiac geometry. 
 
Incidence of LVH was more in patients with widened pulse pressure.  
11(73%) out of 15(30%) of patients with pulse pressure in the range of 51-
60 and 5(62.5%) of 8(16%) with pulse pressure >60 had LVH respectively 
while LVH was seen in 2 patients (29%) and 8 patients (40%) in patients 
with pulse pressure range of <40 and 41-50 respectively. Majority of 
patients in the pulse pressure range of < 40 and 41-50 had normal geometry. 
 
  Among 26 patient with stage II hypertension, 20 (77%) had LVH 
while 6 (25%) of patients with stage I hypertension had LVH. 
 
In patients with proteinuria, 12 (80%) of LVH was in stage II; in 
patients without proteinuria, 8 (72%) of LVH was in stage II hypertension. 
 
Among 27 overweight patients, (70%) 19 had LVH. out of 18 patients 
with proteinuria, 14 (78%) were overweight. 
 
Among 24 patients with stage I hypertension, 18 (75%) had normal 
cardiac geometry and only 5 (21%) had microproteinuria.  
 
Among 26 patients with stage II hypertension, 19 (73%) had LVH of 
which 13 (68%) had microproteinuria.  
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PERERA STUDY  
 
COMPLICATION OUR STUDY PERERA STUDY 
LVH 52% 59% 
PROTEINURIA 36% 42% 
  
Our study results are comparable with study by perera et al.  
 
 
PERERA Study Insisted of 500 Untreated Patients. 
 
 
USPHS STUDY 
 
COMPLICATION OUR STUDY USPHS STUDY 
LVH 52% 9% 
Renal Dysfunction 36% 1% 
 
 
In USPHS Study LVH was based on ECG Findings. The study was 
done in Patients with mild Hypertension, who were treated and followed up 
with placebo.  
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Another Study by O.Kumar et al showed Similar Results. 
 
STUDY TOTAL PROTEINURIA / LVM 
O. Kumar et al 50 44% 
Our Study 50 36% 
 
 
STUDY TOTAL LVH 
SR Gupta et al 50 74% 
Our Study 50 50% 
 
 
TOD OUR STUDY S. A. KHAN et al 
Proteinuria 36% 29.3% 
LVH 50% 44% 
 
 
This study results are compared with study done by S. A. Khan et al, 
Aligarh 
LVH By Echo PROTEINURIA 
 OUR STUDY S. A. KHAN et al 
No 12.5% 11.1% 
Yes 57.6% 38.8% 
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CONCLUSION 
 
Among the fifty patients with newly diagnosed hypertension in the 
age group of 40-70 years majority were in fifth decade. Among the fifty 
patients, 26 had left ventricular hypertrophy and 24 had normal cardiac 
geometry. 
 
In patients with LVH, majority had concentric remodelling, while 
eccentric hypertrophy and concentric hypertrophy occurred with almost 
equal incidence. 
 
 Among 18 patients with microproteinuria, 15 had left ventricular 
hypertrophy showing significant association between proteinuria and left 
ventricular hypertrophy. 
 
Smoking showed significant association with proteinuria. 
 
A significant association was seen between widened pulse pressure 
and LVH Majority of patients with pulse pressure above 50 had LVH. 
While most of the patients with pulse pressure < 50 had normal geometry.    
 
Majority of patients (70%) with proteinuria and LVH were in stage-II 
hypertension. 
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A significant majority of overweight patients had LVH and 
proteinuria. 
 
Patients were almost equally distributed between stage I and II 
Hypertension. Majority of patients had normal cardiac geometry in stage I 
while stage II patients had LVH of whom majority had microproteinuria.  
 
On applying binary logistic regression model for analysis of 
association between age, sex, BMI, smoking, pulse pressure, stage of 
hypertension and LVH; only stage II hypertension had significant 
association with LVH.  
 
On applying binary logistic regression model for analysis of 
association between age, sex, BMI, smoking, pulse pressure, LVH and 
microproteinuria; only abnormal cardiac geometry had significant 
association with microproteinuria.  
 
Our study has shown a significant association between LVH and 
microproteinuria in hypertensive patients; in conformance with different 
studies as quoted above. We can recommend microproteinuria as a 
screening procedure for target organ damage in newly diagnosed 
hypertensive patients so as to select our treatment strategy accordingly.    
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ABBREVIATION 
 
BMI   - Body Mass Index 
LVH   - Left Ventricular Hypertrophy  
MAU  - Micro Albuminuria  
PCR   - Protein – Creatinine Ratio  
LV   - Left Ventricle  
BP   - Blood Pressure  
IVSd   - Inter-Ventricular Septal Thickness at End -  
Diastole   
LVISd  - Left Ventricular Cavity internal Dimension at  
End- Diastole   
PWTd  - Posterior Wall Thickness at End - Diastole  
LVMI  - Left Ventricular Mass Index  
RWT   - Relative Wall Thickness  
CVD  - Cardio Vascular Disease 
CAD   - Coronary Artery Disease   
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PROFORMA FOR DATA COLLECTION 
Name:  
Age:  
Sex: Male /Female  
 
H/o Presenting complaint  
H/o Smoking  
Co-morbidities  
Examination 
Height:  Weight:  BMI:  
Pulse Rate:  
Blood Pressure:  
RS:  CVS:  
Abdomen:  CNS:  
    
70 
 
INVESTIGATION 
RBS:  Blood Urea:  
S.Creatinine  S. 
Sodium/Potassium 
 
S. Fasting 
Cholesterol 
 
Urine Albumin:  Sugar:  Deposits:  
ECG  
CXR-PAView  
ECHO CARDIOGRAPHY 
       LVIDd IVSTd PWTd 
EF  
Valves/RWMA  
Spot Urine PCR  
 
 
